Predicine

Predicine is a private, commercial-stage diagnostics company advancing a next-generation liquid biopsy platform. Its core technology, GeneRADAR, uniquely profiles both DNA and RNA from blood and urine, aiming for more accurate and holistic cancer biomarker detection. The company provides a suite of assay services (e.g., PredicineCARE™, PredicineBEACON™) and partners with biopharma firms to support global clinical trials from its CLIA/CAP labs in the US and China. Predicine is positioned in the high-growth liquid biopsy market, competing on its dual DNA/RNA analysis and urine-based capabilities.

GeneRADAR next-generation liquid biopsy platform for simultaneous analysis of cell-free DNA (cfDNA) and cell-free RNA (cfRNA) from blood and urine, powered by the DeepSEA AI bioinformatics engine.

Predicine competes in the crowded liquid biopsy market against major players like Guardant Health, Exact Sciences, and Natera, which have broader commercial footprints and larger datasets. Its differentiation lies in the simultaneous DNA/RNA analysis from a single tube and its focus on urine-based testing, but it must overcome the scale and brand recognition of its established rivals.